Investors looking to add a growth stock to their portfolio should consider small-cap Hims & Hers Health Inc. (NYSE: $HIMS).
The San Francisco-based %Telehealth company has been on fire lately, with its share price having risen 348% in the past 12 months, including a 68% gain so far in 2025.
The growth is truly astounding when one considers that Hims & Hers was only established in 2017 and went public in 2021.
The company provides prescription medications, over-the-counter medications, and personal care products that are popular with consumers.
The success of Hims & Hers can be attributed to its unique business model that combines doctor consultations with a prescription drug dispensary.
The company’s direct-to-consumer model has consumers consult licensed healthcare professionals and access treatments and medications through its online platform.
In recent years, Hims & Hers has expanded its offerings to include health solutions for both men and women, along with mental health services.
The stock exploded in 2024 after the company announced that it will make GLP-1 weight loss medications available through its site.
Despite the stock’s meteoric rise, it currently has a market capitalization of $9 billion U.S., placing in the small-cap category.
Shares of HIMS are currently trading near an all-time high and the valuation is rich at 97 times future earnings estimates.
But for investors on the hunt for a growth stock, it would be hard to match the current momentum in Hims & Hers Health.
